Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

26 children have joined SciSparc’s two-compound autism treatment trial

Summary by stocktitan.net
At Israel’s Soroka Medical Center, the double-blind study plans to enroll 60 children for 20 weeks and compares SCI-210 with CBD monotherapy.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

stocktitan.netstocktitan.net

26 children have joined SciSparc’s two-compound autism treatment trial

At Israel’s Soroka Medical Center, the double-blind study plans to enroll 60 children for 20 weeks and compares SCI-210 with CBD monotherapy.

Read Full Article
thenewswire.comthenewswire.com

NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Open the article to view the coverage from thenewswire.com

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

thenewswire.com broke the news on Monday, August 31, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Be'er Sheva icon

Be'er Sheva

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal